Type 2 diabetes care Flashcards

(40 cards)

1
Q

What are the microvascular complications of diabetes?

A
  • Retinopathy
  • Nephropathy
  • Foot disease (ulceration)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the macrovascular complications of diabetes?

A
  • Myocardial infarction
  • Stroke
  • Heart failure
  • Peripheral vascular disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the management of macrovascular complications of diabetes? (simple)

A
  • Glycaemic control

* Conventional CV risk factor modification (smoking, BP, Cholesterol)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the biomedical targets for Type 2 diabetes?

A
  • HbA1c: 7% (or individualised)
  • BP: <130/80 (ACEi or ARB, CCB, Thiazide diuretic)
  • Cholesterol: statin if >40 yrs
  • Normal body weight
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the lifestyle measures for type 2 diabetes?

A

•Diet and calorie restriction
- weight watchers
- 800kcal diet with food reintroduction
•Increased physical activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the suffix for DPP-4 inhibitors?

A

Gliptins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the suffix for GLP-1 receptor agonists?

A

Tides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the suffix for SGLT-2 inhibitors?

A

Flozin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the first line drug for T2DM?

A

Metformin (sometimes SU)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the second line drug treatment of T2DM?

A
  • Two agents

* Add SU, Flozin (SGLT-2i), Gliptin (DPP-4 i) or Glitazone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the third line drug treatment?

A
  • Three agents

* Add SU, flozin, Gliptin or Glitazone or start injectable therapy with GLP-1 agonist or insulin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the 4th line drug treatment of T2DM?

A
  • Four agents

* Add SU, Flozin, Gliptin or glitazone or start injectable therapy with insulin or GLP-1 agonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the mechanism of action of metformin?

A
  • Suppress hepatic gluconeogenesis, reducing glucose output from the liver
  • Increases peripheral insulin sensitivity, increasing glucose uptake and utilisation
  • increase AMPK activity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the pros of metformin?

A
  • Moderate efficacy
  • Weight reduction
  • Low hypo risk
  • CV benefit
  • Extensive experience
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the cons of metformin?

A
  • GI side effects
  • Cant use if eGFR<30
  • Small risk of lactic acidosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the mechanism of action of sulfonylureas?

A
  • Close potassium channels on beta cells, stimulating the release of stored insulin
  • Increased cellular uptake and glycogenesis; reduces gluconeogenesis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are the pros of sulfonylureas?

A
  • High efficacy

* Extensive experience

18
Q

What are the cons of sulphonylureas

A
  • No cardiovascular benefit
  • Weight gain
  • High hypo risk
  • Caution in CKD
19
Q

When should you consider prescribing a sulphonylurea first line?

A
  • Metformin not tolerated

* Osmotic symptoms (but once resolved add metformin)

20
Q

What is the mechanism of action of DPP-4 inhibitors?

A
  • Inhibit DPP-4 and enhance the effects of endogenous incretins e.g. GLP-1
  • Increase glucose mediated insulin secretion, suppress glucagon secretion
21
Q

What are the pros of DPP-4 inhibitors?

A
  • Low/moderate efficacy
  • Low hypo risk
  • Few adverse effects
22
Q

What are the cons of DPP-4 inhibitors?

A
  • Weight neutral
  • No CV benefit
  • Reduce dose in CKD
23
Q

What is the mechanism of action of SGLT2i?

A
  • Inhibits SGLT2 in the proximal convoluted tubule of the kidney
  • Decreases renal reabsorption of glucose
24
Q

What are the pros of SGLT2i?

A
  • Moderate efficacy
  • CV benefit (BP and HF)
  • Renal benefit (CANA)
  • Weight loss
  • Low hypo risk
25
What are the cons of SGLT2i?
*  Risk of GU infection | *  Small risk of hypovolaemia/DKA
26
What is the mechanism of action of thiazolidinediones (glitazones)?
*  PPAR gamma receptor agonists | *  Increase the sensitivity of fat, muscles, and liver to endogenous and exogenous insulin
27
What are the pros of glitazones?
*  Moderte efficay *  Probably low CV protection *  Low hypo risk *  Past experience
28
What are the cons of glitazones?
*  Weight gain *  fluid retention *  Fractures
29
Which T2DM drugs cause weight gain?
*  Sulphonylurea *  Glitazone *  Insulin
30
Which T2DM drugs cause weight loss?
*  Metformin *  SGLT2i *  GLP-1 receptor agonists
31
What is the mechanism of action of GLP-1 receptor agonists?
*  Increase glucose mediated insulin secretion *  Suppresses glucagon secretion *  Increases satiety and appetite
32
What are the pros of GLP-1 agonists?
*  High efficacy *  CV benefit *  Low hypo risk *  Weight loss
33
What are the cons of GLP-1 agonists?
*  Injected *  GI side effects *  Uncertain safety re. pancreas
34
What is the mechasnim of action of insulin?
*  Increase glucose uptake and utilisation in skeletal muscle *  Reduces hepatic output, increases glycogenesis *  Decrease lipolysis *  Decrease gluconeogenesis
35
What are the pros of insulin?
*  High efficacy | *  Extensive experience
36
What are the cons of insulin?
*  Injected *  No CV benefit *  Weight gain *  Highest hypoglycaemia risk
37
What should you stop if you add GLP-1 agonist?
DPP-4 inhibitor
38
What are the risks of prescribing in the elderly?
* polypharmacy risk with drug interactions *  Increased likelihood of adverse events to drugs *  Increased likelihood of hypoglycaemia
39
What are the prescribing considerations in renal disease?
*  Stop metformin when eGFR<30ml/min/1.73m2 *  Caution with SU as increased risk of hypoglycaemia *  Dose-dose reduction required for some tides and gliptins *  SGLT2i are less effective at glucose lowering in CKD (eGFR>60) *  Renal protection with CANA
40
What are the prescribing considerations in heart failure?
*  May use metformin in chronic heart failure, withhold during acute episodes of failure *  Stop or do not initiate glitazone *  Flozins reduced hospitalisation for heart failure with and without diabetes